JP2008508287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508287A5 JP2008508287A5 JP2007523709A JP2007523709A JP2008508287A5 JP 2008508287 A5 JP2008508287 A5 JP 2008508287A5 JP 2007523709 A JP2007523709 A JP 2007523709A JP 2007523709 A JP2007523709 A JP 2007523709A JP 2008508287 A5 JP2008508287 A5 JP 2008508287A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- compound
- unsubstituted alkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims 11
- 125000003107 substituted aryl group Chemical group 0.000 claims 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 11
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical group CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 2
- JRAXJFBRKJWNNL-LJJGLLTISA-N 2-amino-4-[[(2s,3r,4s,5s)-5-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methylsulfanyl]butanoic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCCC(N)C(O)=O)N[C@H]1C1=CNC2=C(N)N=CN=C12 JRAXJFBRKJWNNL-LJJGLLTISA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 101710185027 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase Proteins 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 101710081557 Aminodeoxyfutalosine nucleosidase Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 claims 1
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 101150009274 nhr-1 gene Proteins 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59144204P | 2004-07-27 | 2004-07-27 | |
| US61912604P | 2004-10-15 | 2004-10-15 | |
| PCT/US2005/026419 WO2006014913A2 (en) | 2004-07-27 | 2005-07-26 | Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508287A JP2008508287A (ja) | 2008-03-21 |
| JP2008508287A5 true JP2008508287A5 (enExample) | 2008-07-31 |
Family
ID=35787760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523709A Pending JP2008508287A (ja) | 2004-07-27 | 2005-07-26 | ５’−メチルチオアデノシンホスホリラーゼ及び５’メチルチオアデノシン／ｓ−アデノシルホモシステインヌクレオシダーゼの阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090012104A1 (enExample) |
| EP (1) | EP1771452A4 (enExample) |
| JP (1) | JP2008508287A (enExample) |
| AU (1) | AU2005269541A1 (enExample) |
| WO (1) | WO2006014913A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| SI2077268T1 (sl) | 1999-04-08 | 2017-07-31 | Victoria Link Limited | Postopek za pripravo inhibitorjev nukleozidnega metabolizma |
| ES2363766T3 (es) | 2002-08-21 | 2011-08-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibidores de nucleosidasas y fosforilasas de nucleosidos. |
| NZ523970A (en) | 2003-02-04 | 2005-02-25 | Ind Res Ltd | Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases |
| NZ533360A (en) | 2004-06-04 | 2007-02-23 | Ind Res Ltd | Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds |
| US8541567B2 (en) * | 2005-07-27 | 2013-09-24 | Albert Einstein College Of Medicine Of Yeshiva University | Transition state structure of 5′-methylthioadenosine/s-adenosylhomocysteine nucleosidases |
| US8916571B2 (en) | 2006-02-24 | 2014-12-23 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase |
| JP2009528996A (ja) * | 2006-02-24 | 2009-08-13 | インダストリアル リサーチ リミテッド | ヌクレオシドホスホリラーゼ及びヌクレオシダーゼの阻害剤を用いて疾患を処置する方法 |
| EP2049543B1 (en) | 2006-09-07 | 2014-11-05 | Callaghan Innovation Research Limited | Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| CN101528749B (zh) | 2006-09-07 | 2013-07-31 | 工业研究有限公司 | 核苷磷酸化酶和水解酶的无环胺抑制剂 |
| US20100062995A1 (en) * | 2006-09-26 | 2010-03-11 | Schramm Vern L | Transition state structure of human 5'methylthioadenosine phosphorylase |
| KR20090101278A (ko) | 2006-12-22 | 2009-09-24 | 인더스트리얼 리서치 리미티드 | 누클레오시다제 및 포스포릴라제 억제제의 아제티딘 유사체 |
| EP2348854A4 (en) * | 2008-09-22 | 2012-03-14 | Einstein Coll Med | METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING |
| AU2010271532B2 (en) * | 2009-07-17 | 2016-03-03 | Albert Einstein College Of Medicine, Inc. | 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| US9102974B2 (en) * | 2010-09-29 | 2015-08-11 | Florida State University Research Foundation, Inc. | Semi-synthetic quorum sensors |
| CN103193781B (zh) * | 2013-04-01 | 2015-12-23 | 济南大学 | 一种sahn酶蛋白的特异性抑制化合物及其合成方法 |
| WO2017062421A1 (en) | 2015-10-05 | 2017-04-13 | The University Of North Carolina At Chapel Hill | Use of mtap inhibitors for the treatment of lung disease |
| CN116478172B (zh) * | 2023-06-20 | 2023-09-05 | 英矽智能科技(上海)有限公司 | 吡咯并[3,2-d]嘧啶类化合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458799B1 (en) * | 2000-08-31 | 2002-10-01 | Biocryst Pharmaceuticals, Inc. | Deazaguanine analog, preparation thereof and use thereof |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| ES2363766T3 (es) * | 2002-08-21 | 2011-08-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibidores de nucleosidasas y fosforilasas de nucleosidos. |
| US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| US20090227562A1 (en) * | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
-
2005
- 2005-07-26 WO PCT/US2005/026419 patent/WO2006014913A2/en not_active Ceased
- 2005-07-26 US US11/658,794 patent/US20090012104A1/en not_active Abandoned
- 2005-07-26 JP JP2007523709A patent/JP2008508287A/ja active Pending
- 2005-07-26 EP EP05775512A patent/EP1771452A4/en not_active Withdrawn
- 2005-07-26 AU AU2005269541A patent/AU2005269541A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508287A5 (enExample) | ||
| JP2008510770A5 (enExample) | ||
| EP3277276B1 (en) | Methods of administering glutaminase inhibitors | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2017528498A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2014510149A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2017507122A5 (enExample) | ||
| JP2019014758A5 (enExample) | ||
| CN113784970A (zh) | Erk抑制剂及其应用 | |
| JP2019517487A5 (enExample) | ||
| JP2010530881A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2008533191A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2010241830A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2010513523A5 (enExample) | ||
| JP2005518382A5 (enExample) | ||
| JP2009519243A5 (enExample) | ||
| JP2009511508A5 (enExample) |